Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator

Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
American Association of Individual Investors

Why Coherus Oncology, Inc.’s (CHRS) Stock Is Up 21.70%

As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...

Discovery of PITTs shows platelets can switch from clotting to driving vessel inflammation

A team from Würzburg has fundamentally changed our understanding of platelet biology. The researchers demonstrate that the ...
Science Daily

This new antibody may stop one of the deadliest breast cancers

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Single enzyme streamlines production of all four RNA building blocks

A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...

Worried about your thyroid? Here's the simple £10 DIY test that could reveal the truth... and whether these testing kits can really diagnose you with menopause or ca…

You can now investigate your health worries from home, using DIY testing kits that claim to screen for a range of conditions ...

Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE(R)-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone and in ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...